Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MTRAC Reviews - August 2013

MTRAC issued a new Commissioning Support review in August 2013. The review covers mirabegron.

The Mirabegron (Betmiga®) summary advises that this drug is suitable for prescribing in primary care. The committee considered the drug to have a lower place in therapy and relatively weak evidence due to limited comparative data with anti-muscarinics and limited long-term efficacy data. The committee also noted that NICE has recommended this treatment as an option for treating overactive bladder (OAB) only for people in whom anti-muscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects.

Action: Clinicians should be aware of these reviews and use the recommendations to guide appropriate use of these medicines in current practice.

Share 'MTRAC Reviews - August 2013' on Email Share 'MTRAC Reviews - August 2013' on Delicious Share 'MTRAC Reviews - August 2013' on Digg Share 'MTRAC Reviews - August 2013' on Facebook Share 'MTRAC Reviews - August 2013' on Google+ Share 'MTRAC Reviews - August 2013' on reddit Share 'MTRAC Reviews - August 2013' on StumbleUpon Share 'MTRAC Reviews - August 2013' on Twitter

atomic-wealth

No Comments to “MTRAC Reviews - August 2013”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer